The brokerage retained its underperform rating and Rs 326 target price, saying the recent block deal does not materially change Biocon's long-term earnings outlook.
The brokerage retained its underperform rating and Rs 326 target price, saying the recent block deal does not materially change Biocon's long-term earnings outlook.
<iframe src="https://hindustansphere.com/embed/cluster/e9b54aacaa34310effd1a0d615e3aa8d21716ac2" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Biocon-Mylan Share Sale: Bernstein Retains 'Underperform', Flags Three Key Risks Ahead — Check Target Price, Potential Upside And More"></iframe>
